Search Results
Search results for "Addex Therapeutics"
Results found for "Addex Therapeutics"
- 📰 GPCR Weekly News, March 25 to March 31, 2024
cAMP-PKA-CREB signaling pathway based on network pharmacology and bioinformatics analysis Unveiling the therapeutic News Monash University pharmaceutical scientists honoured in NHMRC Research Excellence Awards Domain Therapeutics Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Confo Therapeutics Development In Endocrine And Metabolic Diseases How biotech companies are using AI to design drugs GPCR Therapeutics
- 📰 GPCR Weekly News, April 10 to 16, 2023
Allosteric GPCR Drug Discovery from the 2nd Annual GPCRs-Targeted Drug Discovery Summit, Boston MA Pathios Therapeutics Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics presented 3 posters at AACR 2023 Exscientia presented a poster at AACR 2023 Pathios Therapeutics presented Swiss Biotech Day (April 24 - 25, 2023) ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics
- Ben Clements on Rescuing Opioids with GPCR Modulators
His work highlights how foundational GPCR science can drive therapeutic innovation.
- 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder, Maxion Therapeutics ) – BioLeader Interview Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK
- Nanobodies: New Dimensions in GPCR Signaling Research
the development of more selective drugs capable of modulating specific signaling pathways, improving therapeutic This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending its conformation, protects the Schiff base, and prevents protein degradation, potentially offering therapeutic Nanobodies: A Review of Generation, Diagnostics and Therapeutics.
- Amylin Receptor Signaling: Three Receptors From One, and How to Profile Each
predict its activity at AMY2 or AMY3, and a molecule's selectivity across the set can shape both its therapeutic Answering those questions cleanly, and early, is what separates a rationally designed amylin therapeutic
- 📰 GPCR Weekly News, May 27 to June 2, 2024
tunes mGlu5 receptor function, impacting synaptic transmission Orphan receptor GPR88 as a potential therapeutic the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies Industry News Structure Therapeutics
- GPR108 is required for gambogic acid inhibiting NF-κB signaling in cancer
Herein, we identified GPR108, a GPCR protein described in innate immune system, is a potential therapeutic Overall, our findings supported GPR108 as a promising therapeutic target of cancer, and provided a small
- Allosteric modulation of GPCRs: From structural insights to in silico drug discovery
orthosteric site), allosteric modulators offer new avenues for the regulation of GPCR function with potential therapeutic today, will facilitate structure-based discovery and development of allosteric modulators as novel therapeutic
- When January Looks Different by March: Orthosteric vs. Allosteric Insights from Our Latest AMA
dependence reveals hidden selectivity and efficacy shifts It becomes critical in both screening strategy and therapeutic Habits for Data Quality and Reproducibility Detection assays identify activity; they do not validate therapeutic
- Targeting Intracellular Allosteric Sites in GPCRs
other GPCR-regulated systems such as free fatty acid receptors (FFARs), now regarded as targets for therapeutic and β-arrestin coupling, enabling the development of biased agonists and antagonists with distinct therapeutic Allosteric modulation is gaining prominence in GPCR therapeutics, with the discovery of an intracellular Biased allosteric modulators can enhance the safety and efficacy of GPCR-targeted therapeutics by selectively
- 📰 GPCR Weekly News, May 29 to June 4, 2023
GPCR Activation and Signaling Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides Industry News Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions Domain Therapeutics' Nomination of DT-9045: A Groundbreaking NAM for Immunooncology Structure Therapeutics to Present at Jefferies Healthcare
- 📰 GPCR Weekly News, June 19 to 25, 2023
GPCR Partner, GPCR Therapeutics, for passing the Technology Evaluation process for listing on the KOSDAQ GPCR Therapeutics passes the Technology Evaluation process for listing on KOSDAQ. function" (June 28 - 30, 2023) FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics
- Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System
tools used to manipulate GPCR activity in an orthosteric site-independent manner to compounds with therapeutic development for each receptor, as well as the structural, signaling, pathophysiologic consequences, and therapeutic
- 📰 GPCR Weekly News, August 21 to 27, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities'. neutrophil chemoattractant Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics
- RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany...
So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic
- 📰 GPCR Weekly News, September 25 to October 1, 2023
of traditional Chinese medicine in the treatment of glioblastoma multiforme Industry News Structure Therapeutics Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting
- Unlock the Future of GPCR Science: Breakthroughs and Courses Await | Sep 2 - Sep 8, 2024
Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic September 2nd to 8th, 2024 Industry News Superluminal Medicines Closes $120 Million Series A Round Domain Therapeutics Heterodimer, TAS1R2/1R3 GPCRs in Neuroscience GPCR-Mediated Natural Products and Compounds: Potential Therapeutic
- Building Backwards: Why Top-Down Models Could Revolutionize Pain Research
how inflammation, cognition, and pain circuits overlap , and how GPCRs might serve as more responsive therapeutic
- 📰 Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)
activity, and structural evaluation Flavonoids as G Protein-coupled Receptors Ligands: New Potential Therapeutic back GPCR agonist after GSK changes course All-rounder among receptors inspires drug research Tectonic Therapeutic Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Carmot Therapeutics
- Quantifying Receptor Selectivity in Modern Drug Discovery
Another produces a larger shift in EC₅₀ in one system than another, and we assume we’ve found therapeutic In the end, what matters therapeutically is the integrated response.
- First AMA of 2026: GPCR Pharmacology, Biased Signaling & Mechanistic Clarity
The paper explores: Detection and quantification of signaling bias Influence of biased signaling on therapeutic
- Navigating the Signaling Network: RTK and GPCR Crosstalk Uncovered
This knowledge could inform the development of therapeutic strategies aimed at targeting specific phosphorylation These findings enhance our understanding of cellular signaling dynamics and open new avenues for therapeutic
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
activity without directly competing with ligands, potentially reducing side effects and increasing therapeutic the findings of this study have significant implications for drug design, personalised medicine, and therapeutic
- Chemokine receptor-targeted drug discovery: progress and challenges
The therapeutic approaches mainly include small molecule inhibitors, as well as monoclonal antibodies frequency of administration are particularly rigorous for this class, as the majority of potential therapeutic Overall, the future potential lies in using different therapeutic modalities to modulate the stromal
- GPCR Updates: Celebrating Breakthroughs, New Course Launches Soon, and Exclusive Discounts! | Aug 26 - Sep 1, 2024
Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Modalities A quick revision of how β-adrenergic receptors work and how their antagonists can achieve therapeutic Galien USA ‘Best Startup’ Award: Pioneering GPCR-Driven Immunotherapies in Cancer Treatment Structure Therapeutics
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
cardiometabolic disease, and gain insights into novel approaches in neurodegeneration and antibody therapeutics missed by traditional screening methods, gaining a first-mover advantage in developing more effective therapeutics
- 📰 GPCR Weekly News, April 3 to 9, 2023
GPCRs in Neuroscience G protein-coupled receptors (GPCRs) as Potential Therapeutics for Psychiatric Disorders Domain Therapeutics to present three posters at AACR 2023 annual meeting. Biotech Day (April 24 - 25, 2023) NEW ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
his interview, Regulators of G protein Signaling (RGS proteins) might hold some of the most untapped therapeutic
- 📰 GPCR Weekly News, March 20 to 26, 2023
Industry News Domain Therapeutics was one of the 4 Biotech Trophy nominees at 2023 HealthTech awards. Function Therapeutics has been awarded a Phase 1 SBIR grant from NSF. Function Therapeutics has a new website. Call for GPCR Papers GPCRs: Signal Transduction.












